Apyx Medical Corporation reported a significant increase in financial performance for the second quarter of 2026, with net sales reaching $13.9 million, a 22.1% increase compared to $11.4 million in the same period of 2025. The company's Surgical Aesthetics segment, which includes products like the Renuvion and AYON Body Contouring System, saw a 28.1% rise in sales, totaling $12.4 million, driven by increased demand for its innovative offerings. Gross profit for the quarter was $8.9 million, reflecting a gross margin of 63.9%, up from 62.3% in the prior year, attributed to a favorable product mix and increased sales volume.
In terms of profitability, Apyx Medical reported a net loss of $3.1 million for the second quarter, a slight improvement from a net loss of $3.7 million in the same quarter of 2025. The loss per share was $0.07, compared to $0.09 in the previous year. For the first half of 2026, the company recorded a net loss of $5.2 million, down from $7.9 million in the same period of 2025. The reduction in losses is primarily due to increased sales in the Surgical Aesthetics segment and improved operational efficiencies.
Strategically, Apyx Medical announced the limited commercial launch of its AYON Body Contouring System with power liposuction capabilities, following FDA clearance received in May 2026. This product is expected to enhance the efficiency of fat removal procedures, potentially increasing market share in the cosmetic surgery sector. The company continues to focus on expanding its product offerings and enhancing its operational capabilities, which includes a recent increase in employee headcount to support sales and marketing efforts.
Operationally, Apyx Medical's international sales accounted for approximately 32.2% of total revenues in the second quarter, indicating a growing global footprint. The company sold around 48,000 single-use handpieces in the first half of 2026, up from 40,000 in the same period of 2025. The increase in customer engagement and product adoption rates reflects the company's successful marketing strategies and product innovations. However, the OEM segment experienced a decline in sales, which the company anticipates will continue as it shifts focus towards its Surgical Aesthetics offerings.
Looking ahead, Apyx Medical anticipates ongoing challenges related to cash flow and operational losses, with plans to fund operations through existing cash reserves and potential equity or debt financing. The company remains cautious about the availability of additional financing and its impact on future operations. Management is optimistic about the long-term growth potential of its Surgical Aesthetics segment, particularly as the market for body contouring treatments expands in response to trends in weight loss and cosmetic procedures.
About Apyx Medical Corp
Apyx Medical Corporation develops and manufactures advanced energy medical devices featuring proprietary Helium Plasma Technology, marketed as Renuvion for cosmetic surgery and J-Plasma for hospital surgical applications. Serving plastic surgeons and medical professionals globally, the company offers electrosurgical generators, handpieces, and accessories that deliver precise tissue treatment with controlled heat. Its business model combines direct sales, distributor networks, OEM manufacturing, and a strong focus on innovation, clinical support, and intellectual property protection.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov